UbiVac's DPV-001 Cancer Vaccine Shows 3x Response Rate Improvement in Head and Neck Cancer Trial
Key Insights
UbiVac (search)'s DPV-001 cancer vaccine demonstrated a 3x improvement in response rates and progression-free survival compared to standard-of-care immunotherapy in head and neck squamous cell carcinoma patients.
The "off-the-shelf" immunotherapy contains over 400 Dark Matter-derived antigens designed to target virtually all solid tumors, with more than 34 patients treated to date.
Clinical data showed a 2x improvement in overall survival, 56% response rate in PD-1 (search)-naïve patients versus 19% standard-of-care, and 33% response rate in patients who previously failed anti-PD-1 therapy.
UbiVac (search) announced promising clinical results for its lead cancer vaccine candidate DPV-001, showing significant improvements over standard-of-care treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data, presented at the Parker Institute for Cancer Immunotherapy's Cancer Vaccine Workshop in New York, demonstrated the potential of targeting cancer's "Dark Genome (search)" through the company's novel immunotherapy platform.
Clinical Trial Results Show Strong Efficacy Signals
In UbiVac (search)'s phase Ib combination-immunotherapy trial, DPV-001 delivered substantial improvements across multiple efficacy measures when combined with checkpoint inhibition. The treatment achieved a 3x improvement in both response rates and progression-free survival (PFS) compared to standard-of-care immunotherapy. Overall survival showed a 2x improvement over current treatment options.
The clinical data revealed particularly encouraging results in different patient populations. In PD-1 (search)-naïve patients, DPV-001 combination therapy achieved a 56% response rate compared to 19% with standard-of-care pembrolizumab. Perhaps most significantly for patients with limited treatment options, the therapy demonstrated a 33% response rate in patients who had previously failed anti-PD-1 therapy—a population with significant unmet medical need.
Dr. Bernard A. Fox, Co-founder, President, and CEO of UbiVac (search), presented the two-year follow-up data, stating: "DPV-001's strong improvements in response and survival show the power of targeting cancer's Dark Genome (search). We're excited to advance into phase II and expand this therapy to more patients."
Dark Matter Cancer Antigen Platform
DPV-001 represents what UbiVac (search) describes as an "off-the-shelf" immunotherapy containing over 400 Dark Matter-derived antigens. This approach targets cancer antigens derived from the Dark Genome (search), which the company believes provides significant therapeutic and commercial advantages over competing cancer vaccine approaches.
UbiVac (search) has administered DPV-001 to more than 34 patients and claims to have more than a decade of follow-up safety data. According to Fox, UbiVac believes it has the first Dark Matter/non-canonical cancer immunotherapy that has been administered to patients, positioning it ahead of competitors including Merck (search), BioNTech, CureVac, and myNEO Therapeutics (search).
The broad antigen coverage of DPV-001, combined with its manufacturing advantages and compatibility with checkpoint inhibitors, is designed to target virtually all solid tumors. This positions the therapy as a potentially scalable platform across multiple cancer types.
Market Opportunity and Development Plans
Head and neck squamous cell carcinoma represents a significant global health burden, accounting for approximately 890,000 new cases and 450,000 deaths annually worldwide, making it the sixth most common cancer globally.
UbiVac (search) plans to initiate its Phase II trial focusing on the difficult-to-treat population of patients who have failed prior anti-PD-1 (search) therapy. This represents the next major value inflection point for the company as it advances its platform technology.
The company expects DPV-001 can be developed for combination therapy across multiple major cancer indications, including lung, breast, prostate, brain, melanoma, kidney, liver, colon, and ovarian cancers, representing multi-billion-dollar market opportunities.
Broad Cancer Treatment Potential
Early data suggest that combining DPV-001 with anti-PD-1 (search) therapy and other immunotherapies may enhance outcomes for patients with HNSCC and other solid tumors. UbiVac (search)'s mission focuses on developing immunotherapies that induce broad immunity against many components of cancer, potentially reducing cancer's capacity to escape immune destruction.
The company's platform technology aims to make combination immunotherapy more effective and widely accessible across multiple solid tumor types, addressing a key challenge in current cancer treatment approaches.